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Abstract
Background: The current study was designed to compare antral follicle count (AFC) and basal
ovarian volume (BOV), the exogenous FSH ovarian reserve test (EFORT) and the clomiphene
citrate challenge test (CCCT), with respect to their ability to predict poor and hyper responders.
Methods: One hundred and ten regularly menstruating patients, aged 18–39 years, participated in
this prospective study, randomized, by a computer designed 4-blocks system study into two
groups. Fifty six patients underwent a CCCT, and 54 patients underwent an EFORT. All patients
underwent a transvaginal sonography to measure the basal ovarian volume and count of basal antral
follicle. In all patients, the test was followed by a standard IVF treatment. The result of ovarian
hyperstimulation during IVF treatment, expressed by the total number of follicles, was used as gold
standard.
Results: The best prediction of ovarian reserve (Y) was seen in a multiple regression prediction
model that included, AFC, Inhibin B-increment in the EFORT and BOV simultaneously (Y = -3.161
+ 0.805 × AFC (0.258-1.352) + 0.034 × Inh. B-incr. (0.007-0.601) + 0.511 BOV (0.480-0.974) (r =
0.848, p < 0.001). Univariate logistic regression showed that the best predictors for poor response
were the CCCT (ROC-AUC = 0.87), the bFSH (ROC-AUC = 0.83) and the AFC (ROC-AUC =
0.83). Multiple logistic regression analysis did not produce a better model in terms of improving the
prediction of poor response. For hyper response, univariate logistic regression showed that the
best predictors were AFC (ROC-AUC = 0.92) and the inhibin B-increment in the EFORT (ROC-
AUC = 0.92), but AFC had better test characteristics, namely a sensitivity of 82% and a specificity
89%. Multiple logistic regression analysis did not produce a better model in terms of predicting
hyper response.
Conclusion: In conclusion AFC performs well as a test for ovarian response being superior or at
least similar to complex expensive and time consuming endocrine tests. It is therefore likely to be
the test for general practise.
Published: 15 March 2007
Reproductive Biology and Endocrinology 2007, 5:9 doi:10.1186/1477-7827-5-9
Received: 29 November 2006
Accepted: 15 March 2007
This article is available from: http://www.rbej.com/content/5/1/9
© 2007 Kwee et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
Page 2 of 10
(page number not for citation purposes)
Background
Real time two-dimensional (2D) pelvic ultrasonography
is a relatively accurate and reliable method of determining
ovarian volume and morphology [1]. Interobserver and
intraobserver measurements have been shown to be very
low when using transvaginal sonography [2,3].
The mean ovarian volume increases from 0.7 ml at 10
years to 5.8 ml at 17 years of age [4]. It has been suggested
that there are no major changes in ovarian volume during
reproductive years until the premenopausal period. In
women > 40 years old, there is a dramatic drop in ovarian
volume, which is not related to parity [2,4,5]. Thereafter
there is a further sharp decline in size in postmenopausal
women which seems mostly related to the time when
menstruation ceases, rather than merely to age, because
when oestrogen treatments were given, there appeared to
be no decrease in ovarian volume with age [5].
Several studies [6-8] demonstrate that ovarian volume, as
determined by transvaginal ultrasonography, is a predic-
tor of ovarian reserve and clinical pregnancy rate. Lass et
al. [9] confirmed that decrease in ovarian volume is an
early sign of depletion of the follicles and its measurement
is likely to be clinically useful.
A cohort of follicles measuring 2–5 mm is present very
early in the follicular phase of the cycle [10]. These folli-
cles are in an early antral phase, and are easily detected by
transvaginal ultrasound, as they contain a small amount
of antral fluid. The number of small follicles at the begin-
ning of the cycle may well represent the actual functional
ovarian reserve. So the number of small antral follicles are
clearly related to age and could well reflect the size of the
remaining primordial pool in women with proven natural
fertility [11,12].
Previously [13], we published the comparison of endo-
crine tests for the prediction of the total number of folli-
cles obtained after stimulation. With linear regression
analysis, Inhibin B-increment and E2-increment in the
EFORT gave the best predictive values. We tried to find
one single, simple test, which could identify poor, normal
and hyper responders [14] and concluded that by logistic
regression analysis, the bFSH + sFSH in the CCCT was the
best endocrine test to predict poor responders, unfortu-
nately not for the prediction of hyper responders. The aim
of the current study was to compare the antral follicle
count (AFC) and the basal ovarian volume (BOV), with
the exogenous FSH ovarian reserve test (EFORT) and the
clomiphene citrate challenge test (CCCT), with respect to
their ability to predict poor and hyper responders.
Methods
Study population
One hundred and ten patients, aged 18–39 years, who
were eligible for treatment by Intra Uterine Insemination
(IUI) between June 1997, to December 1999, participated
in the study. This study is part of a prospective rand-
omized study of regular menstruating patients to the
determination of ovarian reserve [13]. Their infertility was
either idiopathic for > 3 years and/or due to a male factor
and/or cervical hostility. Cervical hostility was diagnosed
by means of a well timed negative postcoital test, that is,
no progressive motile spermatozoa seen at a magnifica-
tion of 400× in good cervical mucus despite normal
semen parameters.
Patients had to have regular menstrual cycles with an ovu-
lation, which was confirmed by a biphasic body tempera-
ture chart and an endometrium biopty dating in the luteal
phase, two ovaries and showed two patent tubes with hys-
terosalpingography or at least one patent Fallopian tube
with no further pathology with diagnostic laparoscopy.
They were naive for IVF treatment. Excluded were patients
with an oligo- or amenorrhoea (9 or fewer cycles a year)
or a severe male factor, defined as (1) less than 1 million
motile spermatozoa after Percoll centrifugation (gradient
40/90) and/or (2) > 20% antibodies present on the sper-
matozoa after processing with Percoll centrifugation (gra-
dient 40/90) and/or (3) > 50% of the spermatozoa
without an acrosome. Other exclusion criteria were
untreated or insufficiently corrected endocrinopathies,
clinically relevant systemic diseases, or a body mass index
> 28 kg/m2.
The protocol was approved by the Institutional Review
Board and the Committee on ethics of research involving
human subjects of the Vrije Universiteit Medical Centre,
Amsterdam, the Netherlands. All the couples participating
in the study signed informed consent.
Treatment protocol
Patients were randomized by a computer designed 4-
blocks system into two groups [13]. Fifty six patients
underwent a transvaginal sonography to measure the
basal ovarian volume and count of basal antral follicle
and a Clomiphene citrate challenge test (CCCT), and 54
patients underwent an transvaginal sonography to meas-
ure the basal ovarian volume and count of basal antral fol-
licle and an Exogenous Follicle stimulating hormone
Ovarian Reserve Test (EFORT). In all patients, the test was
followed by an IVF treatment under a long protocol. The
bFSH level, bE2 level and bInhibin B level were deter-
mined as an integral part of all CCCT's and EFORT's, as
described previously [13]. Van der Meer et al. [15] showed
that in eumenorrheic patients, the median (range) FSH
threshold level for monofollicular growth was 5.3 (4.3–Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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8.2) IU/l and the median (range) threshold dose was 75
IU (0.5–1.75) FSH/day.
The FSH threshold was determined by a low dose step-up
regimen of FSH given intravenously after pituitary desen-
sitization with GnRH agonist. It was concluded that by an
increment of 1/2 ampoule of FSH (37.5 IU) above the
threshold dose for monofollicular growth, the maximum
response is already obtained. It seems that in IVF stimula-
tion maximal effect is reached with FSH dosages up to 225
IE [16-18]. Combining these facts, it can be concluded
that an initial stimulation by 3 ampoules of 75 IU of FSH
under a long (GnRH agonist suppressed) protocol, prob-
ably gives a maximal IVF stimulation, the outcome of
which could be used as the gold standard for the cohort
size.
Transvaginal sonography measurements
All ultrasound examinations were performed by one of
the authors (J.K, R.S) using an Aloka SSD-1700 ultra-
sound apparatus (5.0 MHz probe).
The volume of each ovary was calculated by measuring in
three perpendicular directions and applying the formula
for an ellipsoid: (D1 × D2 × D3 × π/6). The volumes of
both ovaries were added for the total basal ovarian vol-
ume (BOV).
To determine the diameter of the follicle, the mean of
measurements in two perpendicular directions was taken.
The numbers of follicles in both ovaries were added for
the total antral follicle count (AFC). The follicles visual-
ized and counted by TVS in the early follicular phase are
2–10 mm in size.
Clomiphene citrate challenge test (CCCT)
starting on the fifth day of the menstrual cycle (CD 1 = day
of onset of menses) 100 mg of Clomiphene citrate
(Serophene®; Serono, Geneva, Switzerland) was adminis-
tered for 5 days. In this study on CD 2 or 3 (basal values)
and on CD 10 (stimulated values) the serum FSH was
determined. Analysis of the CCCT [13] was performed by
the parameter: bFSH + sFSH.
Exogenous Follicle stimulating hormone Ovarian Reserve Test 
(EFORT)
on CD 3, 300 IU recFSH (Gonal-F®, Serono, Geneva, Swit-
zerland) were administered subcutaneously (s.c). In this
study blood samples for the determination of FSH, E2 and
Inhibin B were drawn: just before (basal values) and 24
hrs after (stimulated values) the administration of FSH.
Analysis of the EFORT [13] included the following param-
eters: E2-increment and Inhibin B-increment 24 hrs after
administration of FSH.
IVF-treatment
The ovarian hyperstimulation protocol was performed
according to a long GnRH-agonist protocol starting in the
midluteal phase. On CD 3 of the first cycle the ovarian
volume and antral follicle count was measured by trans-
vaginal sonography (TVS) examinations as described
above. Also on CD 3 the CCCT or the EFORT was per-
formed as described above. In the subsequent midluteal
phase, seven days after ovulation, daily s.c. injections with
triptoreline-acetate (Decapeptyl®, 0.1 mg/day; Ferring,
Hoofddorp, the Netherlands) were started. Because of the
administration of the GnRH-agonist, patients were
advised to use a barrier type of contraception during this
cycle. On CD 3 of the next cycle, ovarian hyperstimulation
was started with daily s.c. injections of a fixed dose of 225
IU uFSH (Metrodin HP®, 75 IU/amp; Serono, Geneva,
Switzerland), because this dosage probably gives a maxi-
mal effect in follicle stimulation. Standard procedures
were followed including transvaginal sonography (TVS)
(Aloka SSD-1700, 5.0 MHz probe) on CD 2 or 3 and on
CD 9 or 10. Daily TVS was performed from the moment
when the leading follicle reached a diameter of 16 mm.
Ovarian hyperstimulation was continued until the largest
follicle reached a diameter of at least 18 mm. The maxi-
mum duration of uFSH administration allowed was 16
days. If these criteria were met, Metrodin HP®  and
Decapeptyl® were discontinued and 10.000 IU of hCG
(Profasi®, 10.000 IU/amp; Serono, Geneva, Switzerland)
were administered. On the day of hCG, TVS was per-
formed to count the result of ovarian hyperstimulation
(all follicles = 10 mm) expressed as the total number of
follicles. TVS guided follicular aspiration (FA) was per-
formed 36 hours after hCG administration. On the day of
hCG administration E2 was determined. Follicular aspira-
tion was done under systemic analgesia (7.5 mg diazepam
orally and 50–100 mg pethidine hydrochloride intramus-
cularly), and all follicles present were aspirated.
Serum assay
Serum E2 was determined by a competitive imunoassay
(Amerlite, Amersham, UK). For E2, the inter-assay CV was
11% at 250 pmol/l and 8% at 8000 pmol/l, the intra-assay
coefficient of variation (CV) was 10% at 350 pmol/l. 8%
at 1100 pmol/l and 8% at 5000 pmol/l. The lower limit of
detection for E2 was 90 pmol/l. In the EFORT and CCCT
we measured E2 by a sensitive radioimmunoassay (Sorin,
Biomedica, Saluggia, Italy). This measurement of E2 was
abbreviated as EE. For EE, the inter-assay CV was 11% at
60 pmol/l, 8% at 200 pmol/l, 11% at 550 pmol/l and 8%
at 900 pmol/l. The intra-assay CV was 4% at 110 pmol/l
and 5% at 1000 pmol/l. The lower limit of detection for
EE was 18 pmol/l. FSH was determined by a commercially
available immunometric assay (Amerlite, Amersham,
UK). For FSH, the inter-assay CV was 9% at 3 IU/l and 5%
at 35 IU/l, the intra-assay CV was 9% at 5 IU/l, 8% at 15Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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IU/l and 6% at 40 IU/l. The lower limit of detection for
FSH was 0.5 IU/l. Inhibin B was determined immunomet-
rically by a commercially available assay (Serotec Limited
Oxford UK). For Inhibin B, the inter-assay CV was 17% at
25 ng/L, 14% at 55 ng/L and 9% at 120 ng/L and the intra-
assay CV was 8% till 40 ng/l and 5% at > 40 ng/l. The
lower limit of detection for Inhibin B was 13 ng/l.
Half-way through the study (after 62 patients), the Amer-
lite assay used to assess FSH was withdrawn from the mar-
ket and was replaced by another commercially available
assay (Delfia, Wallac, Finland). The two assays have been
compared and showed excellent linear correlation,
although a shift in the values took place (Delfia FSH =
1.28 × Amerlite FSH + 0.01 (r = 0.9964)). For the Delfia
FSH, the inter-assay CV was 5% at 3.5 IU/l and 3% at 15
IU/l. All FSH determinations have been recalculated and
are expressed according to the Delfia assay. The lower
limit of detection for FSH was 0.5 IU/l.
Values below the detection limit of an assay were assigned
a value equal to the detection limit of that assay.
Statistical analysis
The outcome measure of the first part of this study was the
result of ovarian hyperstimulation expressed as the
number of follicles. In our former study [13], we esti-
mated the value of the independent variables by univari-
ate linear regression, age, bFSH, CCCT-results, E2-
increment in EFORT, inhibin B-increment in EFORT. In
this study, we estimated by univariate linear regression,
the value of the independent variables: total basal ovarian
volume and the total basal antral follicle count in predict-
ing the ovarian response. Stepwise regression analysis was
used to find a prediction model for the ovarian response.
The R square of the correlation of these variable(s) with
the total number of follicles obtained after stimulation
reflects the proportion of the variability of the number of
follicles explained by this variable(s).
The outcome measure of the second part of this study was
the result of ovarian hyperstimulation expressed as the
number of retrieved oocytes.
We defined a 'poor' ovarian response as less than 6
oocytes after ovarian hyperstimulation in an IVF treat-
ment and a 'hyper' response as more than 20 oocytes after
such an IVF treatment. Among women undergoing in
vitro fertilization, the chances of a live birth are related to
the number of eggs fertilized, presumably because of the
greater selection of embryos for transfer. The low success
rate when only two eggs were fertilized reflects the lack of
choice among embryos for transfer [19]. We have in our
laboratory the experience that we have an overall 50–60%
chance of fertilisation. Taken this togheter, at least 6
oocytes are required for three or more fertilized eggs.
We defined a hyper response when there were > 20
oocytes. This was based on the knowledge that the preg-
nancy rates do not increase when > 20 oocytes are
retrieved. Moreover, such cases have a significant risk of a
severe OHSS [14].
In our former study [14], we examined the value of the
independent variables by univariate logistic regression:
age, bFSH, binhibin B, CCCT-results, E2-increment in
EFORT, inhibin B-increment in EFORT. In this study we
examined by univariate logistic regression, the value of
the independent variables: total basal ovarian volume and
the total basal antral follicle count in predicting the ovar-
ian response in predicting a poor and hyper response after
ovarian hyperstimulation in IVF. Subsequently multivari-
ate logistic regression analyses were used to develop pre-
diction models for the ovarian response. The area under
the receiver operating characteristic curve (ROC-AUC)
was computed to assess the predictive accuracy of the
logistic models. ORT evaluation using ovarian response as
reference or outcome variable should imply the assess-
ment of predictive accuracy and clinical value of the test.
Accuracy refers to the degree by which the outcome condi-
tion is predicted correctly. Summary statistics of accuracy
include sensitivity (rate of correct identification of cases
with poor response) and specificity (rate of correct identifi-
cation of cases without poor response). To identify all
cases that will respond poorly to stimulation without
judging many normal responders badly, the test must
have high sensitivity and high specificity.
The Receiver Operating Characteristic curve (ROC curve)
is a plot of the true positive rate against the false positive
rate for the different possible cutpoints of a diagnostic
test. An ROC curve demonstrates the tradeoff between
sensitivity and specificity (any increase in sensitivity will
be accompanied by a decrease in specificity). The closer
the curve follows the left-hand border and then the top
border of the ROC space, the more accurate the test. The
area under the ROC curve provides information on the
overall discriminatory capacity of the test. Values of 1.0
imply perfect and that of 0.5 indicate completely absent
discrimination.
To define a 'normal' and an 'abnormal' test, sensitivity,
specificity, positive predictive value and accuracy were
used to find the optimal cut off level.
Comparison of means was done with the unpaired t-test.
For all tests the significance level was 0.05.Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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Statistical analysis of the data was performed with SPSS
(Statistical package for Social Sciences; SPSS, Inc., Chi-
cago, IL) for Windows.
Results
The characteristics of the two groups are given as means ±
SD in Table 1[13]. No significant differences were noted
between the groups in baseline characteristics, cycle day 3
measurements or outcome parameters. In the first group
68% had a primary infertility and 32% a secondary infer-
tility. The cause of infertility was for 65% an idiopathic
factor, 31% a male factor and 4% a cervical factor. In the
second group, 60% had a primary infertility and 40% a
secondary infertility. The cause of infertility was for 66%
an idiopathic factor, 38% a male factor and 6% a cervical
factor.
In the CCCT group 32 patients had a normal response to
ovarian stimulation, 15 patients had a poor response and
8 patients had a high response. One patient was excluded
from analysis because of a severe risk on ovarian hyper-
stimulation syndrome (OHSS) (the E2 level exeeded
35.000 pmol/l after ovarian hyperstimulation). In the
EFORT group 32 patients had a normal response to ovar-
ian stimulation, 14 patients had a poor response and 8
patients had a high response.
Univariate linear regression analysis
The correlation between the total basal ovarian volume
(BOV) and number of follicles obtained after stimulation
and the correlation between the count of the total basal
antral follicle (AFC) and number of follicles obtained
after stimulation are calculated. The regression line of the
basal ovarian volume on the number of follicles (Figure
1A) was drawn by the regression equitation: X = -0.211 +
1.239 × tot. Volume; with a 95% CI of 0.909–1.569,
meaning that each increment of 1 ml of ovarian volume
predicts an increment of 1.2 follicle (95% CI: 0.9–1.6) (r
= 0.610, P < 0.001). The regression equitation for the total
basal antral follicle (Figure 1B), X = -0.568 + 1.479 × tot.
antral foll. (1.222–1.736), shows that an increase of 1
antral follicle predicts an increment of 1.5 follicles (r =
0.741, P < 0.001).
Table 2: Univariate regression analysis of the ovarian reserve tests for the prediction of the stimulative cohort of the ovaries (ovarian 
reserve).
N Correlation P
Age (y) 110 0.423 < 0.001
bFSH (IU/l) 110 0.313 0.001
bFSH + sFSH in the CCCT (IU/l) 56 0.496 < 0.001
E2-increment in the EFORT (pmol/l) 54 0.751 < 0.001
Inh.B-increment in the EFORT (ng/l) 54 0.718 < 0.001
Total ovarian volume (ml) 110 0.610 < 0.001
Total antral follicle count 110 0.745 < 0.001
Table 1: Characteristics of the groups (values are means ± SD). No significant differences
CCT-group
N = 56
EFORT-group
N = 54
Baseline characteristics
Age (y) 33.79 ± 3.95 34.19 ± 3.75
Duration infertility (y) 3.71 ± 2.08 3.87 ± 1,56
Cycle day 3
FSH (IU/l) 7.60 ± 2.46 7.38 ± 3.11
E2 (pmol/l) 126.05 ± 53.10 118.60 ± 47.06
Inhibin B (ng/l) 94.95 ± 39.36 96.33 ± 40.60
Total volume (ml) 10.91 ± 5.19 12.10 ± 4.69
Total antral follicle count 9.41 ± 5.00 10.66 ± 5.21
Treatment results
Duration of stimulation (d) 12.4 ± 2.7 11.9 ± 2.3
Number of ampoules of FSH 34.2 ± 8.0 32.7 ± 7.0
E2 level on the day of hCG (pmol/l) 11155.41 ± 18591.13 12134.78 ± 17872.12
Endpoints
Total number of follicles 14.27 ± 10.23 14.17 ± 10.27
Total number of oocytes 11.58 ± 8.51 11.93 ± 9.11Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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(A) Plot of the number of follicles obtained after stimulation against the basal total ovarian volume Figure 1
(A) Plot of the number of follicles obtained after stimulation against the basal total ovarian volume. The three lines represent 
the regression line: Y = -0.460 + 1.255 × tot. ovarian volume with the 95% confidence interval (CI) of the mean. (B) Plot of the 
number of follicles obtained after stimulation against the basal total antral follicle count. The three lines represent the regres-
sion line: Y = -0.730 + 1.491 × tot. antral follicle count with the 95% CI of the mean.
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Table 2 shows the results of the EFORT and CCCT as
described in our previous study [13] and the additional
results of the transvaginal ultrasound.
Stepforward regression analysis: Prediction model for 
ovarian reserve
Based on the CCCT group, the prediction model for ovar-
ian response is explained for 51% by the best predictive
variable: the total antral follicle count. When adding the
independent variables: total basal volume, bFSH + sFSH,
bFSH and age in a stepforward regression analysis, the
explained variation rose significantly with 5% after the
selection of bFSH. The independent variable total basal
volume, ∑ bFSH + sFSH and age, did not have a significant
contribution to the model. The exact prediction of the
total number of follicles obtained after stimulation thus
increased from 51% to 56%. The regression line of the
bFSH and total antral follicle count on the number of fol-
licles was drawn by the regression equation: Y = 9.478 -
0.985 × bFSH (-1.857- -1.150) + 1.122 × AFC (0.698 -
1.561) (r = 0.748, p < 0.001).
Based on the EFORT group, the prediction model for ovar-
ian response is explained for 63% by the best predictive
variable, the total antral follicle count. When adding the
Inhibin B-increment and total basal volume simultane-
ously in a stepforward multiple regression prediction
model, the explained variation of the best predictive
model rose significantly with 9%. The total explained var-
iation thus increased from 63% to 72%. The regression
line of the total antral follicle count, Inhibin B-increment
and total basal volume on the number of follicles was
drawn by the regression equation: Y = -3.161 + 0.805 ×
AFC (0.258-1.352) + 0.034 × Inh. B-incr. (0.007-0.601) +
0.511 BOV (0.480-0.974) (r = 0.848, p < 0.001). When we
included E2-increment, age and bFSH as variables in the
stepforward regression analysis together with total antral
follicle count, Inhibin B-increment and the total basal
ovarian volume we did not find a significant contribution
of these variables.
Univariate logistic regression
Table 3 depicts the ROC-AUC for the total basal ovarian
volume and the total basal antral follicle count for the pre-
diction of poor response after IVF with ovarian hyperstim-
ulation and also the results of the EFORT and CCCT as
described previously [14]. Both tests have the potential to
predict poor response, expressed by the ROC-AUC (0.83
respectively, 0.77).
Table 4 presents test characteristics such as sensitivity, spe-
cificity, positive predictive value and accuracy at different
cut off levels of the AFC to define a normal (non-poor
response) and an abnormal (poor response) test for the
Table 3: Univariate and multivariate logistic regression analysis and areas under the receiver operating characteristic curve (ROC-
AUC) of the ovarian reserve tests for the prediction of 'poor' response in IVF.
Variable N P ROC AUC
Univariate analysis
Age (y) 110 0.033 0.63
bFSH (IU/l) 110 < 0.0001 0.83
bFSH + sFSH in the CCCT (IU/l) 56 < 0.0001 0.88
E2-increment in the EFORT (pmol/l) 54 0.006 0.75
Inh.B-increment in the EFORT (ng/l) 54 < 0.0001 0.86
Total ovarian volume (ml) 110 < 0.0001 0.77
Total antral follicle count 110 < 0.0001 0.83
Multivariate analysis
CCCT GROUP
bFSH + sFSH in the CCCT (IU/l)) 56 < 0.0001 0.88
Multivariate analysis
EFORT GROUP
Total antral follicle count 54 0.003 0.88
Table 4: Sensitivity, specificity, positive predictive value (PPV) for positive test results and proportion of patients (accuracy) with a 
correct prediction at different cut off levels for the total antral follicle count (AFC) for the prediction of 'poor'response in IVF.
Total AFC Sensitivity Specificity PPV Accuracy
< 4 0.21 0.99 0.86 0.78
< 5 0.28 0.99 0.89 0.80
< 6 0.41 0.95 0.75 0.89
< 7 0.69 0.80 0.56 0.77
< 8 0.76 0.74 0.51 0.75Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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prediction of 'poor'response after IVF. The cut off level of
< 6 antral follicles had a sensitivity of 41% and a specifi-
city of 95%. In the population studied, with a prevalence
of 27% for a poor response (< 6 oocytes after ovarian
hyperstimulation in an IVF treatment), the accuracy was
89% (which means that 89% of the patients had a cor-
rectly predicted test). In case of a result less than 6 antral
follicles, the test correctly predicted poor response to stim-
ulation in an IVF-treatment in 75% (positive predictive
value).
Table 5 depicts ROC-AUC for the total basal ovarian vol-
ume and the total basal antral follicle count for the predic-
tion of hyper response after IVF with ovarian
hyperstimulation and also the results of the EFORT and
CCCT as described previously [14]. As a single prognostic
predictor, the AFC appeared to have a good discriminative
potential for hyper response, expressed by a large ROC-
AUC (0.92).
Table 6 presents test characteristics such as sensitivity, spe-
cificity, positive predictive value and accuracy at different
cut off levels of the AFC to define a normal (non-high
response) and an abnormal (hyper response) test for the
prediction of hyper response after IVF. The cut off level of
> 14 antral follicles gave the highest sum of the sensitivity,
specificity and gave also the highest accuracy. This result
had a sensitivity of 82% and a specificity of 89%. In the
population studied, with a prevalence of 15% for high
response (> 20 oocytes after ovarian hyperstimulation in
an IVF treatment), the accuracy was 88% (which means
that 88% of the patients had a correct predicted test). In
case of a result of greater than 14 antral follicles, the test
correctly predicted hyper response to stimulation in an
IVF-treatment in 58% (positive predictive value).
Multivariate logistic regression
In the CCCT group, multivariate analysis for poor
response resulted in a model with 1 variable: bFSH + sFSH
in the CCCT (ROC-AUC = 0.88).
In the EFORT group, multivariate analysis for poor
response resulted in a model with only one variable: Total
antral follicle count (ROC-AUC = 0.88) (Table 3).
In the CCCT group, multivariate analysis for hyper
response resulted in a model with 2 variables: age and
AFC (ROC-AUC = 0.93).
In the EFORT group, multivariate analysis for hyper
response resulted in a model with only one variable: AFC
(ROC-AUC = 0.93) (Table 5).
Table 5: Univariate and multivariate logistic regression analysis and areas under the receiver operating characteristic curve (ROC 
AUC) of the ovarian reserve tests for the prediction of hyper 'response' in IVF.
Variable N P ROC AUC
Univariate analysis
Age (y) 110 0.004 0.71
BFSH (IU/l) 110 < 0.0001 0.80
bFSH + sFSH in the CCCT (IU/l) 56 0.003 0.82
E2-increment in the EFORT (pmol/l) 54 0.003 0.83
Inh.B-increment in the EFORT (ng/l) 54 < 0.0001 0.92
Total ovarian volume (ml) 110 < 0.0001 0.87
Total antral follicle count 110 < 0.0001 0.92
Multivariate analysis
CCCT GROUP
Age 56 0.032 0.93
Total antral follicle count 56 <0.0001
Multivariate analysis
EFORT GROUP
Total antral follicle count 54 <0.0001 0.93
Table 6: Sensitivity, specificity, positive predictive value (PPV) for positive test results and proportion of patients (accuracy) with a 
correct prediction at different cut off levels for the total antral follicle count (AFC) for the prediction of 'hyper'response in IVF.
Total AFC Sensitivity Specificity PPV Accuracy
> 10 0.94 0.71 0.36 0.76
> 12 0.88 0.80 0.44 0.81
> 14 0.82 0.89 0.58 0.88
> 16 0.47 0.96 0.67 0.88
> 18 0.29 0.98 0.71 0.87Reproductive Biology and Endocrinology 2007, 5:9 http://www.rbej.com/content/5/1/9
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Discussion
AFC is able to accurately predict the number of follicles
obtained during maximal ovarian stimulation. According
to our study that uniquely allowed direct comparison,
AFC does not seem superior to other common basal and
stimulated endocrine ovarian reserve tests. Included into
the stepwise forward multiple regression model it leads,
in combination with the Inhibin B-increment in the
EFORT and BOV, to the most optimal prediction model.
On the other hand, according to logistic analysis, AFC
sofar seems to be the only test able to reliably predict low
and high responders.
Reproductive aging is thought to be dictated by a gradual
decrease in both the quantity and the quality of the
oocytes and follicles held within the ovaries [20,21]. With
regard to quantity, histological studies have shown that at
birth a few million primordial follicles are present from
which at the onset of puberty only some 400.000 are left
[22-25]. The wasting of follicles continuous throughout
reproductive life, reaching a critical number of a few thou-
sand at a mean age of 45 when menstrual cycles become
irregular, and falling to clearly below a thousand follicles
at the time menstrual cycles cease, the event know as men-
opause [26-28]. In analogy to these histological changes,
Scheffer et al. [11] demonstrated that the number of pri-
mordial follicles in the ovary, as published by Faddy and
Gosden [29] correlated well with the number of growing
follicles, counted by transvaginal sonography in the early
follicular phase. So the decreasing size of the antral follicle
cohort with age is a reflection of the decreasing primordial
follicle pool. We used this principle to measure ovarian
reserve, defined as the total number of follicles which can
be stimulated under maximal ovarian stimulation with
FSH. A number of the so-called ovarian reserve tests are
supposed to indirectly reflect the size of the cohort of
small antral follicles (2–10 mm in diameter) in the ovary.
This decrease in follicle number is exemplified by the
increased risk of producing a poor response in ovarian
hyperstimulation in IVF patients at older age [30-32].
A gradual decrease with advancing age in the number of
sonographically detectable antral follicles has been shown
in many studies [3,25]. In recent years several papers have
been published concerning the relation between the
antral follicle count (AFC, defined as the total number of
antral follicles, sized 2–5 or 2–10 mm, present in both
ovaries) and the ovarian response in IVF [10,33], as well
as the occurrence of the menopausal transition [34], indi-
cating that this parameter relates strongly to the quantita-
tive aspects of ovarian reserve.
The performance of AFC with regard to the prediction of
poor response gave a sensitivity of 73% and a specificity
of 95%, which would imply that the test performs only
moderately, especially at the sensitivity level. In compari-
son with CCCT this sensitivity is lower whereas specificity
seems the same. Consequently there would be more false
negative patients with potential undertreatment as result.
Increasing the threshold of AFC implies better sensitivity
and to some extent, a still acceptable specificity. However
the decrease of accuracy indicates that overall an unac-
ceptable number of patients will be misdiagnosed.
Recently Hendriks et al [35], published a meta-analysis on
the AFC as a predictor for poor ovarian response and con-
cluded that AFC is an adequate test for the prediction of
poor ovarian response, comparing to bFSH. The data of
our study that does meet the criteria for inclusion in this
meta analysis would fit seamlessly into the summary ROC
curve of report. We confirm the previous observation of
the little difference between CCCT and AFC [36].
The high intercycle stability of AFC [8] and its potentially
likely attractive cost features, although formal cost effect
comparison studies need to be done, are likely to make
this test rather attractive for routine practice.
A great advantage of AFC over any other test is its potential
usefulness for its ability to concomitantly predict low and
high responders. So far EFORT seemed to have the best
grades [14] but the current analysis provides evidence that
AFC is superior. The test characteristics show us that an
AFC > 14 could lead to the decision to adjust the gonado-
trophin dose in trying to prevent a hyper response leading
to OHSS. Of course the choice of the cut-off level depends
on the appreciation of false positive and false negative
results and on the consequences drawn by the clinician
from an abnormal test.
Total volume of the ovaries detected by transvaginal ultra-
sound is correlated with the outcome parameters but not
better than the count of antral follicles. Its performance
was slightly to moderately less than that of AFC, both for
poor and high response. Our data agree well with that
published in a recent meta analysis [37].
In conclusion AFC performs well as a test for ovarian
response being superior or at least similar to complex
expensive and time consuming endocrine tests, probably
most applicable in general practise.
Future studies will have to be carried out to determine if
other ovarian reserve tests such as the measurement of
Anti-Müllerian Hormone (AMH) [38-40] are better pre-
dictors for ovarian reserve.
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